The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies

References

• Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29:74–81.
   PubMed Web of Science ®Google Scholar
• Duberg AS, Pettersson H, Aleman S, Blaxhult A, Daviethsdottir L, Hultcrantz R, et al. The burden of hepatitis C in Sweden: a national study of inpatient care. J Viral Hepat 2011;18:106–18.
   PubMed Web of Science ®Google Scholar
• Scandiatransplant. The nordic liver transplant registry. 2013. Available from http://www.scandiatransplant.org/. Cited 29 November 2013.
   Google Scholar
• Duberg A, Janzon R, Bäck E, Ekdahl K, Blaxhult A. The epidemiology of hepatitis C virus infection in Sweden. Euro Surveill 2008;13.
   PubMedGoogle Scholar
• Folkhälsomyndigheten. Public Health Agency of Sweden, Homepage, Hepatitis C statistics. 2014. Available from http://www.folkhalsomyndigheten.se/amnesomraden/statistik-och-undersokningar/sjukdomsstatistik/hepatit-c/. Cited 27 March 2014.
   Google Scholar
• Duberg AS, Törner A, Davidsdottir L, Aleman S, Blaxhult A, Svensson Å, et al. Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study. J Viral Hepat 2008;15:538–50.
   PubMed Web of Science ®Google Scholar
• Duberg A. Hepatitis C virus infection: a nationwide study of associated morbidity and mortality [Dissertation]. Örebro University; Örebro, Sweden: 2009.
   Google Scholar
• Socialstyrelsen. The National Board of Health and Welfare; Homepage. 2014. Available from http://www.socialstyrelsen.se/english. Cited 27 March 2014.
   Google Scholar
• Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014;383:515–23.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211–21.
   PubMed Web of Science ®Google Scholar
• Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin. N Engl J Med 2014;370:1594–603.
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 2014;21:60–89.
   PubMed Web of Science ®Google Scholar
• Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J Viral Hepat 2014;21:34–59.
   PubMed Web of Science ®Google Scholar
• Bruggmann P, Berg T, Ovrehus AL, Moreno C, Brandao Mello CE, Roudot-Thoraval F, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 2014;21:5–33.
   PubMed Web of Science ®Google Scholar
• Statistics Sweden. Startpage. 2013. Available from http://www.scb.se/en_/. Cited 3 December 2013.
   Google Scholar
• Norda R, Duberg AS, Sönnerborg A, Olcen P. Transmission of hepatitis C virus by transfusion in Orebro County, Sweden, 1990-1992. Scand J Infect Dis 1995;27:449–52.
   PubMed Web of Science ®Google Scholar
• Shev S, Hermodsson S, Lindholm A, Malm E, Widell A, Norkrans G. Risk factor exposure among hepatitis C virus RNA positive Swedish blood donors--the role of parenteral and sexual transmission. Scand J Infect Dis 1995;27:99–104.
   PubMed Web of Science ®Google Scholar
• Hoffmann G, Berglund G, Elmståhl S, Eriksson S, Verbaan H, Widell A, et al. Prevalence and clinical spectrum of chronic viral hepatitis in a middle- aged Swedish general urban population. Scand J Gastroenterol 2000;35:861–5.
   PubMed Web of Science ®Google Scholar
• Duberg AS, Hansdotter F, How AL, Holmström A, Lesko B. [Important with generous sampling for hepatitis C after blood transfusion. The National Board of Health and Welfare’s new recommendation for risk groups]. Lakartidningen 2013;110:1477–9.
   PubMedGoogle Scholar
• Lidman C, Norden L, Kåberg M, Kall K, Franck J, Aleman S, et al. Hepatitis C infection among injection drug users in Stockholm Sweden: prevalence and gender. Scand J Infect Dis 2009;41:679–84.
   PubMed Web of Science ®Google Scholar
• Ydreborg M, Söderström A, Håkanson A, Alsiö Å, Arnholm B, Malmström P, et al. Look-back screening for the identification of transfusion-induced hepatitis C virus infection in Sweden. Scand J Infect Dis 2011;43:522–7.
   PubMed Web of Science ®Google Scholar
• Lindh M, Hannoun C. Genotyping of hepatitis C virus by Taqman real-time PCR. J Clin Virol 2005;34:108–14.
   PubMed Web of Science ®Google Scholar
• Shev S, Widell A, Foberg U, Fryden A, Hermodsson S, Lindh G, et al. HCV genotypes in Swedish blood donors as correlated to epidemiology, liver disease and hepatitis C virus antibody profile. Infection 1995;23:253–7.
   PubMed Web of Science ®Google Scholar
• Westin J, Lindh M, Lagging LM, Norkrans G, Wejstål R. Chronic hepatitis C in Sweden: genotype distribution over time in different epidemiological settings. Scand J Infect Dis 1999;31:355–8.
   PubMedGoogle Scholar
• Månsson AS, Moestrup T, Nordenfelt E, Widell A. Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program. Scand J Infect Dis 2000;32:253–8.
   PubMed Web of Science ®Google Scholar
• Stenkvist J, Weiland O, Sönnerborg A, Blaxhult A, Falconer K. High HCV treatment uptake in the Swedish HIV/HCV co-infected cohort. Scand J Infect Dis 2014;46:624–32.
   PubMed Web of Science ®Google Scholar
• Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289–93.
   PubMed Web of Science ®Google Scholar
• Lagging M, Wejstål R, Uhnoo I, Gerden B, Fischler B, Friman S, et al. Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations. Scand J Infect Dis 2009;41:389–402.
   PubMed Web of Science ®Google Scholar
• Lagging M, Duberg AS, Wejstål R, Weiland O, Lindh M, Aleman S, et al. Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations. Scand J Infect Dis 2012;44:502–21.
   PubMed Web of Science ®Google Scholar
• Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int 2014;34:69–78.
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM, New Hepatitis C. Therapies: The Toolbox, Strategies, and Challenges. Gastroenterology 2014;146:1176–92.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, et al. Retreatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin. N Engl J Med 2014;370:1604–14.
   PubMed Web of Science ®Google Scholar
• Ackefors M, Nystrom J, Wernerson A, Gjertsen H, Sönnerborg A, Weiland O. Evolution of fibrosis during HCV recurrence after liver transplantation--influence of IL-28B SNP and response to peg-IFN and ribavirin treatment. J Viral Hepat 2013;20:770–8.
   PubMed Web of Science ®Google Scholar
• Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008;49:274–87.
   PubMed Web of Science ®Google Scholar
• Bruno S, Shiffman ML, Roberts SK, Gane EJ, Messinger D, Hadziyannis SJ, et al. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 2010;51:388–97.
   PubMed Web of Science ®Google Scholar
• Syed E, Rahbin N, Weiland O, Carlsson T, Oksanen A, Birk M, et al. Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis. Scand J Gastroenterol 2008;43:1378–86.
   PubMed Web of Science ®Google Scholar
• Weiland O, Hollander A, Mattsson L, Glaumann H, Lindahl K, Schvarcz R, et al. Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin. J Viral Hepat 2008;15:641–5.
   PubMed Web of Science ®Google Scholar
• Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004;53:744–9.
   PubMed Web of Science ®Google Scholar
• Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013;59:434–41.
   PubMed Web of Science ®Google Scholar
• Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: The randomized PILLAR study. Hepatology 2013;58:1918–29.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878–87.
   PubMed Web of Science ®Google Scholar
• Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in Patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014;146:1669–79.
   PubMed Web of Science ®Google Scholar
• Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889–98.
   PubMed Web of Science ®Google Scholar
• Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483–93.
   PubMed Web of Science ®Google Scholar
• Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis. N Engl J Med 2014;370:1973–82.
   PubMed Web of Science ®Google Scholar
• Talal AH, LaFleur J, Hoop R, Pandya P, Martin P, Jacobson I, et al. Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients. Aliment Pharmacol Ther 2013;37:473–81.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, Lawitz E, et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C). J Hepatol 2014;60:741–7.
   PubMed Web of Science ®Google Scholar
• Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013;58:1598–609.
   PubMed Web of Science ®Google Scholar
• CAN. CAN Homepage, Drugs in Sweden. 2013. Available from http://www.can.se/sv/In-English/. Cited 4 December 2013.
   Google Scholar
• Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867–77.
   PubMed Web of Science ®Google Scholar
• Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, et al. A Risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis 2013;57:230–6.
   PubMed Web of Science ®Google Scholar
• Stokkeland K, Duberg AS, Montgomery SM, Franck J, Hultcrantz R. Alcohol dependence increases the mortality risk in patients with hepatitis C. Hepatology 2013;58(S1):p. 1284A.
   Google Scholar